Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 Q4 2016 10 KA - Arbutus Biopharma Corp | exhibit322q4201610-ka.htm |
| EX-31.2 - EXHIBIT 31.2 Q4 2016 10-KA - Arbutus Biopharma Corp | exhibit312q4201610-ka.htm |
| EX-31.1 - EXHIBIT 31.1 Q4 2016 10K/A - Arbutus Biopharma Corp | exhibit311q4201610-ka.htm |
| EX-10.67 - EXHIBIT 10.67 REVISED REDACTED ALEXION - Arbutus Biopharma Corp | exhibit1067alexionagreemen.htm |
| 10-K/A - 10-K/A - Arbutus Biopharma Corp | a2016arbutus10-ka.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K/A of Arbutus Biopharma Corporation (the “Company”) for the year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company. |
Date: May 17, 2017
/s/ Mark Murray | |
Name: Mark Murray | |
Title: President and Chief Executive Officer | |